{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:48:57Z","timestamp":1792514937724,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014598","name":"mannkind corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014598","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40262-021-01084-0","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T06:02:45Z","timestamp":1636783365000},"page":"413-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus"],"prefix":"10.1007","volume":"61","clinical-trial-number":[{"clinical-trial-number":"nct02470637","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0022-6873","authenticated-orcid":false,"given":"Marshall","family":"Grant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8346-2037","authenticated-orcid":false,"given":"Tim","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2752-9855","authenticated-orcid":false,"given":"Robert","family":"Baughman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"key":"1084_CR1","unstructured":"Afrezza [package insert]. Westlake Village (CA): MannKind Corporation; 2018."},{"key":"1084_CR2","unstructured":"MannKind Corporation. Afrezza\u00ae (insulin human) inhalation powder approved in Brazil. In: Investors: press releases. 3 Jun 2019. https:\/\/investors.mannkindcorp.com\/news-releases\/news-release-details\/afrezzar-insulin-human-inhalation-powder-approved-brazil. Accessed 16 Jun 2021."},{"key":"1084_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12189","author":"D R\u00fcppel","year":"2017","unstructured":"R\u00fcppel D, Dahmen R, Boss A, et al. A population dose-response model for inhaled Technosphere Insulin administered to healthy subjects. CPT Pharmacometrics Syst Pharmacol. 2017. https:\/\/doi.org\/10.1002\/psp4.12189.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1084_CR4","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2114","author":"RHA Becker","year":"2007","unstructured":"Becker RHA, Frick AD, Nosek L, Heinemann L, Rave K. Dose-response relationship of insulin glulisine in subjects with type 1 diabetes. Diabetes Care. 2007. https:\/\/doi.org\/10.2337\/dc06-2114.","journal-title":"Diabetes Care"},{"key":"1084_CR5","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2337\/diab.43.3.396","volume":"43","author":"D Howey","year":"1994","unstructured":"Howey D, Bowsher R, Brunelle R, Woodworth J. [Lys(B28), Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes. 1994;43:396\u2013402.","journal-title":"Diabetes"},{"key":"1084_CR6","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-1998","author":"S Steiner","year":"2002","unstructured":"Steiner S, Pf\u00fctzner A, Wilson B, Harzer O, Heinemann L, Rave K. Technosphere\/Insulin: proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes. 2002. https:\/\/doi.org\/10.1055\/s-2002-1998.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1084_CR7","doi-asserted-by":"publisher","DOI":"10.4155\/tde.13.77","author":"C Smutney","year":"2013","unstructured":"Smutney C, Grant M, Kinsey P. Device factors affecting pulmonary delivery of dry powders. Ther Deliv. 2013. https:\/\/doi.org\/10.4155\/tde.13.77.","journal-title":"Ther Deliv"},{"key":"1084_CR8","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2013-0427","author":"B Heurtault","year":"2014","unstructured":"Heurtault B, Reix N, Meyer N, et al. Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification. Clin Chem Lab Med. 2014. https:\/\/doi.org\/10.1515\/cclm-2013-0427.","journal-title":"Clin Chem Lab Med"},{"key":"1084_CR9","volume-title":"Clinical pharmacokinetics and pharmacodynamics: concepts and applications","author":"M Rowland","year":"2011","unstructured":"Rowland M, Tozer T. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2011.","edition":"4"},{"key":"1084_CR10","volume-title":"Pharmacokinetic and pharmacodynamic data analysis: concepts and applications","author":"J Gabrielsson","year":"2000","unstructured":"Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 4th ed. Stockholm: Swedish Pharmaceutical Press; 2000.","edition":"4"},{"key":"1084_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-016-0418-6","author":"T Heise","year":"2017","unstructured":"Heise T, H\u00f6velmann U, Zijlstra E, Stender-Petersen K, Jacobsen J, Haahr H. A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus. Drugs Aging. 2017. https:\/\/doi.org\/10.1007\/s40266-016-0418-6.","journal-title":"Drugs Aging"},{"key":"1084_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0473-5","author":"T Heise","year":"2017","unstructured":"Heise T, Stender-Petersen K, H\u00f6velmann U, et al. Pharmacokinetic and pharmacodynamic properties of faster-acting insulin aspart versus insulin aspart across a clinically relevant dose range in subjects with type 1 diabetes mellitus. Clin Pharmacokinet. 2017. https:\/\/doi.org\/10.1007\/s40262-016-0473-5.","journal-title":"Clin Pharmacokinet"},{"key":"1084_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199701)14:1<63::AID-DIA298>3.0.CO;2-F","author":"L Heinemann","year":"1997","unstructured":"Heinemann L, Traut T, Heise T. Time-action profile of inhaled insulin. Diabet Med. 1997. https:\/\/doi.org\/10.1002\/(SICI)1096-9136(199701)14:1%3c63::AID-DIA298%3e3.0.CO;2-F.","journal-title":"Diabet Med"},{"key":"1084_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13099","author":"J McGill","year":"2020","unstructured":"McGill J, Weiss D, Grant M, Jones M, Kendall D, Hoogwerf B. Understanding inhaled Technosphere Insulin: results of an early randomized trial in type 1 diabetes mellitus. J Diabetes. 2020. https:\/\/doi.org\/10.1111\/1753-0407.13099.","journal-title":"J Diabetes"},{"key":"1084_CR15","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0200","author":"H Akturk","year":"2018","unstructured":"Akturk H, Snell-Bergeon JK, Rewers A, et al. Improved postprandial glucose with inhaled Technosphere Insulin compared with insulin aspart in patients with type 1 diabetes on multiple daily injections: the STAT study. Diabetes Technol Ther. 2018. https:\/\/doi.org\/10.1089\/dia.2018.0200.","journal-title":"Diabetes Technol Ther"},{"key":"1084_CR16","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0075","author":"B Bode","year":"2015","unstructured":"Bode B, McGill J, Lorber D, et al. Inhaled Technosphere Insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care. 2015. https:\/\/doi.org\/10.2337\/dc15-0075.","journal-title":"Diabetes Care"},{"key":"1084_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/193229681200600406","author":"A Boss","year":"2012","unstructured":"Boss A, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin. J Diabetes Sci Technol. 2012. https:\/\/doi.org\/10.1177\/193229681200600406.","journal-title":"J Diabetes Sci Technol"},{"key":"1084_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14202","author":"ER Seaquist","year":"2020","unstructured":"Seaquist ER, Blonde L, McGill JB, et al. Hypoglycaemia is reduced with use of inhaled Technosphere\u00ae Insulin relative to insulin aspart in type 1 diabetes mellitus. Diabet Med. 2020. https:\/\/doi.org\/10.1111\/dme.14202.","journal-title":"Diabet Med"},{"key":"1084_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00643.x","author":"M Hompesch","year":"2006","unstructured":"Hompesch M, Troupin B, Heise T, et al. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. Diabetes Obes Metab. 2006. https:\/\/doi.org\/10.1111\/j.1463-1326.2006.00643.x.","journal-title":"Diabetes Obes Metab"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01084-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01084-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01084-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T05:06:08Z","timestamp":1646283968000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01084-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01084-0","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"9 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Sanofi. Medical writing and editorial assistance were funded by MannKind Corporation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MG is a paid employee of MannKind Corporation and may hold stock and stock options with the company and is listed as an inventor on several MannKind Corporation patents. TH has received research funds from Adocia, Afon Technology, AstraZeneca, Biocon, Boehringer Ingelheim, Eli Lilly, Gan Lee Pharmaceuticals, Johnson&Johnson, Julphar, Mylan, Nestl\u00e9, Neuraly, Nordic Bioscience, Novo Nordisk, Sanofi, and Zealand Pharma and has received speaker honoraria and travel grants from Eli Lilly and Novo Nordisk; he is also a member of advisory panels for Novo Nordisk and Valbiotis. RB is on several MannKind Corporation patents.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Independent Ethics Committee (\u00c4rztekammer Nordrhein) and the Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (Federal [German] Institute for Drugs and Medical Products).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained prior to the conduct of any study-related procedures.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Consent to publish anonymized data was obtained as part of the informed consent.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data sets generated and\/or analyzed during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the design, conduct\/data collection, analysis, and writing of the manuscript and approve the manuscript for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}